Public Health
Insights on disease prevention and control, health promotion and education, environmental health and health equity and social justice.
Assessing strategies for mitigating infectious diseases
Public health officials turn to evidence as the basis for their health policies to control the spread of infections. However, many nuanced factors can influence variations in the number of infections caused by a single infected individual.
Watch the webinar: An introduction to infectious disease modelling
In this whitepaper, we explain the basic measures used to quantify infectious disease transmission and introduce the principles of dynamic modelling to inform the selection of the most effective and cost-efficient strategies for mitigating infectious diseases.
Antimicrobial resistance
The World Health Organization calls antimicrobial resistance, resulting from the overuse of antibiotics or other drugs, one of the top 10 public health threats. In fact, the next global pandemic could be another novel respiratory pathogen of zoonotic origins or a multidrug resistant strain of a previously eradicated pathogen.
In this whitepaper we provide a framework for understanding the antimicrobial crisis and the role healthcare and biopharma industries have to play in mitigating the impact of future pandemics.
Fortifying vaccines: Preparation and prevention against future infectious disease epidemics
This whitepaper presents infrastructural and strategic considerations for strengthening vaccine development so that the medical community will be prepared to respond to future pandemics and novel diseases.
A multifaceted risk factor:
Addressing obesity's impact across the disease spectrum
2.8 million people die every year as a result of obesity. At the same time, investment in research and development for obesity therapies is ushering in a new era of effective medications for this disease. Explore the implications of obesity as a risk factor across the disease spectrum, and how this may impact treatment, drug development and clinical trials for obesity.
ICON survey report:
Trends and challenges in obesity research and clinical trials
This survey investigates the opinions, experiences and predictions of a variety of individuals best positioned to provide an overview of current obesity drug and device development — and where it is likely to go in the future.
The evolution of HIV treatments
HIV is highly heterogeneous, creating barriers to diagnosing and treating the disease. Moreover, the HIV epidemic varies by region and country, necessitating different clinical research strategies across geographies. In this whitepaper, we discuss opportunities for addressing these challenges, best practices for managing infectious disease clinical trials and recent developments in HIV treatment.
Pandemic respiratory vaccine clinical trials: A departure from business as usual
Vaccine trials for respiratory viruses, even in the best of circumstances, present a number of operational challenges for researchers, many of which are exacerbated in the face of a pandemic created by a novel virus. We focus on the corresponding success factors that can keep pandemic respiratory vaccine trials running at optimal speed and efficiency.
COVID-19 vaccines: Post-authorisation safety surveillance
This whitepaper explores the multifaceted challenges of COVID-19 post-authorisation safety surveillance studies and how business intelligence tools can benefit these efforts.
Diversity & inclusion in clinical trials
Examining how the field of clinical research currently approaches diversity and inclusion gives us a baseline understanding on which we can build and make the necessary changes for improvement in the future. ICON looked at the barriers to accessing under-represented subgroups, the regulatory landscape and how organisations are addressing this issue and brings together the findings in this whitepaper.
Public Health media and blogs
-
Media article: Early-phase study design considerations for long-term follow-up in vaccine clinical trials
ICON experts discuss why strategic early planning is key to long-term follow-up in vaccine trials—driving stronger protocols, regulatory alignment, and meaningful outcomes.
-
Blog: Beyond tradition: An analysis of modern vaccine technologies
This blog explores some of the most promising non-viral vaccine development platforms, highlighting their mechanisms, advantages, and limitations.
-
Blog: Why long-term follow-up should start early in vaccine trials
Learn more about why demonstrating long-term safety should start early in vaccine trials. With early planning, vaccine developers can gather real-world data and evidence needed to help individuals make informed decisions about vaccination.
-
Blog: SDoH data for efficient, patient-centred clinical trials
The social determinants of health (SDoH) are a key component of understanding and delivering better outcomes for patients.
-
Blog: Looking forward: The most significant 2024 US healthcare trends - Part 5 of 5
When discussing the 5 biggest challenges that await the healthcare industry in 2024, US politics is a key issue. America is clearly divided on many issues, including those involving government spending, healthcare reimbursements, and treatment coverage issues.
-
Blog: Looking forward: The most significant 2024 US healthcare trends—Part 4 of 5
Given that some of the overall physical- and mental-health indicators show negative progress even while healthcare costs are rising, it begs the question: What is the reason for the backslide?
-
Blog: Looking forward: The most significant 2024 US healthcare trends—Part 3 of 5
Physical- and mental-health measure declines are 2 factors likely to impact the healthcare industry as they move forward in 2024 and beyond. Not surprisingly, concerns over rising healthcare costs and how to best control them continue to dominate in significance.
-
Blog: Looking forward: The most significant 2024 US healthcare trends - Part 2 of 5
In addition to physical health indicators, mental health declines also serve as a measure of the serious health concerns to the healthcare industry in the United States.
Science-led. Mission driven.
At ICON, our dedicated Government and Public Health Solutions team have been advancing the future of global health for over 30 years. Discover more about their work with US Government and NGOs.